The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis.
The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis.
复制标题
DOI：
10.1080/10717544.2017.1413446
复制
发表时间：
2018-11
期刊：
影响因子：
6
通讯作者：
Wang LN
中科院分区：
文献类型：
--
作者：
Liu J;Wang LN
神经退行性运动障碍主要包括帕金森病、非典型帕金森病、亨廷顿病和遗传性共济失调。利鲁唑是美国食品和药物管理局批准的唯一治疗肌萎缩侧索硬化症的药物。在神经退行性运动障碍的实验模型上观察了利鲁唑的神经保护作用。本研究旨在系统分析利鲁唑治疗神经退行性运动障碍的疗效和安全性。计算机检索PubMed、EMbase、CINAHL、Cochrane图书馆和中国国家知识基础设施等电子数据库，直到2017年6月为止，检索符合条件的随机对照试验以及未发表和正在进行的试验。对于连续数据，如果研究没有使用相同的量表来衡量结果，我们计算标准化平均差异和95%的可信区间。对于二分数据，如果试验报告没有不良事件或辍学，我们计算风险差异。我们使用随机效应模型汇集了结果。我们包括了9项研究，涉及1320名神经退行性运动障碍患者，比较了利鲁唑和安慰剂。在发生不良事件的参与者数量上没有发现显著差异，但在遗传性共济失调方面有运动改善。只有两项研究关注神经保护作用。利鲁唑对神经退行性运动障碍患者耐受性良好。利鲁唑对遗传性共济失调患者的症状疗效似乎很有希望，这需要在未来的精心设计的研究中进一步证实。此外，设计着眼于利鲁唑在改善疾病中的神经保护作用的长期研究是有意义的。
Neurodegenerative movement disorders mainly include Parkinson’s disease, atypical parkinsonisms, Huntington disease, and hereditary ataxia. Riluzole is the only drug approved by the US Food and Drug Administration for amyotrophic lateral sclerosis. The neuroprotective effects of riluzole have been observed in experimental models of neurodegenerative movement disorders. In this paper, we aimed to systematically analyze the efficacy and safety of riluzole for patients with neurodegenerative movement disorder. We searched the electronic databases such as PubMed, EMBASE, CINAHL, Cochrane Library and China National Knowledge Infrastructure until June 2017 for the eligible randomized controlled trials, as well as the unpublished and ongoing trials. For continuous data, we calculated standardized mean differences with 95% confidence intervals if studies did not use the same scales to measure outcomes. For dichotomous data, we calculated risk differences if a trial reported no adverse events or dropouts. We pooled the results using a random-effects model. We included nine studies with 1320 patients with neurodegenerative movement disorders, which compared riluzole with placebo. No significant difference was found in the number of participants with adverse events but with motor improvement in hereditary ataxia. There were only two studies focusing on neuroprotective effect. Riluzole is well-tolerated in the patients with neurodegenerative movement disorders. Riluzole seems to be promising for patients with hereditary ataxia in symptomatic effect, which needs to be further confirmed by well-designed studies in the future. Moreover, it makes sense to design long-term study focusing on neuroprotective effect of riluzole in disease-modifying.
登录
查看更多内容
影响因子：
8.6
作者：
Schiefer, J;Landwehrmeyer, GB;Kosinski, CM
通讯作者：
Kosinski, CM
DOI：
10.7916/d8q23xdx
发表时间：
2014
期刊：
Tremor and other hyperkinetic movements (New York, N.Y.)
影响因子：
--
作者：
Liu J;Bader B;Danek A
通讯作者：
Danek A
影响因子：
11.2
作者：
Landwehrmeyer, G. Bernhard;Dubois, Bruno;Ludolph, Albert C.
通讯作者：
Ludolph, Albert C.
影响因子：
168.9
作者：
Schapira, Anthony H. V.;Olanow, C. Warren;Bezard, Erwan
通讯作者：
Bezard, Erwan
影响因子：
8.6
作者：
Bara-Jimenez, William;Dimitrova, Tzvetelina D.;Chase, Thomas N.
通讯作者：
Chase, Thomas N.